CLBIO.ST
Corline Biomedical AB [CLBIO.ST] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
CLBIO.ST Stock Summary
Top 10 Correlated Stocks
CLBIO.ST
In the News
CLBIO.ST Financial details
Company Rating
-
Market Cap
242.85M
Income
-1.81M
Revenue
25.03M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
13
Optionable
No
Shortable
Yes
Earnings
30 Apr 2024
P/E
-363.54
Forward P/E
-
PEG
20.82
P/S
11.69
P/B
3.36
P/C
-
P/FCF
-25.67
Quick Ratio
3.13
Current Ratio
4.68
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.08
EPS next Y
-
EPS next Q
-
EPS this Y
-176.55%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-31.78%
Revenue last 5Y
88.06%
Revenue Q/Q
17.59%
EPS Q/Q
-436.14%
-
-
-
-
SMA20
-2.52%
SMA50
3.4%
SMA100
6.24%
Inst Own
-
Inst Trans
-
ROA
-1%
ROE
-1%
ROC
-0.01%
Gross Margin
105%
Oper. Margin
-3%
Profit Margin
-3%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
9.52-19.85
52W High
-46.58%
52W Low
+12.78%
RSI
52.42
Rel Volume
0.02
Avg Volume
9.35K
Volume
193
Perf Week
4.64%
Perf Month
-6.88%
Perf Quarter
28.48%
Perf Half Y
27.19%
-
-
-
-
Beta
0.475
-
-
Volatility
0.27%, 0.26%
Prev Close
1%
Price
10.15
Change
0.5%
Company Profile
- Volume Average 9.35K
- Market Capitalization 242.85M
- Employee 13
- CEO Dr. Henrik Nittmar Ph.D.
- Headquarters Uppsala,SE
- IPO Date 2015-06-03
-
Website
https://www.corline.se 
Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications. Its products are based on Corline Heparin Conjugate (CHC) technology, a heparin conjugate that is used as stand-alone pharmaceutical compound. The company's products include Renaparin for use in the treatment of end stage renal failure; Cytoparin, a cell therapy that is used for the treatment of patients with type 1 diabetes; CHC, which is used for the treatment of soft tissue injuries; medical devices; and CHS, a coronary stent. The company was founded in 1991 and is based in Uppsala, Sweden.
